Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials

Affiliations

• ¹ Oregon Medical Research Center, Portland, OR, USA.
• ² Institute and Comprehensive Center for Inflammatory Medicine, University of Luebeck, Luebeck, Germany.
• ³ Alliance Clinical Research and Probity Medical Research, Waterloo, ON, Canada.
• ⁴ Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
• ⁵ Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Berlin, Germany.
• ⁶ Pusan National University Hospital, Busan, South Korea.
• ⁷ Janssen Research & Development, LLC, Spring House, PA, USA.
• ⁸ Janssen Scientific Affairs, LLC, Horsham, PA, USA.
• ⁹ Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA.
• ¹⁰ Department of Dermatology, Icahn School of Medicine at Mt Sinai, New York, NY, USA.
• ¹¹ Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA, USA.
• ¹² The University of Melbourne, St Vincent's Hospital Melbourne and Probity Medical Research, Skin Health Institute, Carlton, VIC, Australia.